In conclusion, we propose a novel paradigm, where response to atezo/bev in aHCC is driven by clonally expanded, cytotoxic CD8 TEMRA characterized by a high degree of TCR sharing with peripheral blood and present in the tumour prior to therapy. The gene discussed is CD8A; the disease is neoplasm.